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Theprevalence of obesity is increasingworldwide, with high fat diet (HFD) as one of themain contributing factors.Obesity increases
the predisposition to other diseases such as diabetes through various metabolic pathways. Limited availability of antiobesity drugs
and the popularity of complementary medicine have encouraged research in finding phytochemical strategies to this multifaceted
disease. HFD induced obese Sprague-Dawley rats were treated with an extract of Morinda citrifolia L. leaves (MLE 60). After
9 weeks of treatment, positive effects were observed on adiposity, fecal fat content, plasma lipids, and insulin and leptin levels.
The inducement of obesity and treatment with MLE 60 on metabolic alterations were then further elucidated using a 1H NMR
based metabolomics approach. Discriminating metabolites involved were products of various metabolic pathways, including
glucose metabolism and TCA cycle (lactate, 2-oxoglutarate, citrate, succinate, pyruvate, and acetate), amino acid metabolism
(alanine, 2-hydroxybutyrate), choline metabolism (betaine), creatinine metabolism (creatinine), and gut microbiome metabolism
(hippurate, phenylacetylglycine, dimethylamine, and trigonelline). Treatment with MLE 60 resulted in significant improvement
in the metabolic perturbations caused obesity as demonstrated by the proximity of the treated group to the normal group in the
OPLS-DA score plot and the change in trajectory movement of the diseased group towards the healthy group upon treatment.
1. Introduction
The new understanding of obesity and its related disorders
has resulted in a renewed interest in finding antiobesity
agents from nature, with partial success [1]. An established
antiobesity agent, such as green tea polyphenols, is one of
the few plants extracts reported to reduce weight in both
animals and human subjects [2–4]. Others include extracts
of Nomame Herba, cocoa, and chitin/chitosan [5–7]. While
these studies yielded significant information on the effect
of those plants on diet induced obesity and its biochemical
changes, the overall effect onmetabolic responses is relatively
unknown.
Metabolomics as a new bioanalytical technique in obe-
sity research is still largely unexplored. This “omics” tech-
nique is concerned with the high throughput identification
and quantification of small molecules (<1500Da) in the
metabolome, the collection of small metabolites present in
a cell, organ, or organism [8]. So far, the main applica-
tion of the metabolomics approach has been in toxicolog-
ical and pharmaceutical research, having the potential of
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“bridging Traditional Chinese Medicine (TCM) and molec-
ular pharmacology” [9]. Metabolomics has been applied
for extracts characterisation and quality control of herbal
supplements [10]. In regard to disease biomarkers discov-
ery, metabolomics, in combination with multivariate data
analysis, has been used for the profiling of various biofluids
[11, 12]. More specifically to obesity research, it has been
used to discriminate betweenmetabolites of the obesemodels
and the healthy models [13–15]. Metabolites such as betaine,
taurine, acetone/acetoacetate, phenylacetylglycine, pyruvate,
lactate, and citrate were the main discriminating metabolites
between the obese and lean groups [13]. There is also the
emerging trend of using metabolomics as a platform to
study the holistic efficacy of traditional medicine. 1H NMR
based metabolomics approach was used to assess the effect
of Xue-Fu-Zhu-Yu decoction (XFZYD) on high fat diet
induced hyperlipidemia in rats. Metabolomics analysis of the
plasma, combined with multivariate data analysis, revealed
that XFZYD improved hyperlipidemia by regulating major
metabolic pathways such as decreasing the accumulation
of ketone bodies, enhancing glutathione biosynthesis, and
reversing disturbances in lipid and energy metabolism [16].
Morinda citrifolia L., commonly called noni or Indian
Mulberry, was discovered by the Polynesians more than 2000
years ago and brought to southeast Asia during migration
[17]. Different parts of the plant have a long history of
safe use and were reported to have many health promoting
properties [18] including antidyslipidemic effects in rats [19]
and inhibition of digestive and metabolic lipases in vitro
[20–22]. We recently showed (results under publication) that
a rutin rich extract of Morinda citrifolia leaves (MLE60)
prevented weight and fat mass gain in lean Sprague-Dawley
rats fed with a high fat diet with an improvement in plasma
lipids, leptin, and insulin profiles and increased fecal fat
output.
In this study, we assessed the effects of the leaf extract in
high fat diet induced obesemale Sprague-Dawley rats, using a
1HNMRmetabolomics approach, analysing urine and serum
for markers metabolites.
2. Methodology
2.1. Preparation of Morinda citrifolia Leaf Extract (MLE 60).
Mature M. citrifolia leaves were obtained from 5 represen-
tative trees from Bukit Expo, Universiti Putra Malaysia, Ser-
dang, Selangor, Malaysia. Voucher specimens were deposited
at the herbarium, Institute of Bioscience, Universiti Putra
Malaysia (SK2197/13), and species were confirmed as M.
citrifolia L. The leaves were immediately quenched using
liquid nitrogen and lyophilised under pressure (−50∘C, 48–
72 hours, LABONCO, Labonco Corporation, Kansas City,
Missouri, USA) until constant weight.The dried plant sample
was ground using a commercial grinder, sieved, and stored at
−80∘C until further use.
Dried plant materials were extracted with 60% ethanol at
room temperature for 72 hours. Filtrate was collected every
24 hours and the pooled filtrate was rotary-evaporated under
vacuum until being concentrated. The aqueous phase was
frozen at −80∘C and lyophilised under pressure (−50∘C, 48
hours) and stored at −80∘C until future use. Extracts were
prepared by dissolving weighed amount of extract in 0.03%
carboxymethyl cellulose (CMC).
2.2. Animal Experiment. Male Sprague-Dawley rats (3 weeks
old) were purchased from Sapphire Enterprise, Malaysia, and
acclimatized for 10 days under standard laboratory conditions
(12 h light/dark cycle, 55–60% relative humidity, 23–25∘C).
After acclimatization, rats were randomly divided into 2
groups based on assigned diets: standard rat chow (Gold
Coin,Malaysia) and a high saturated fat diet for 12 weeks (MP
Diets, USA). The body weight of each rat in both groups was
recordedweekly to ensure development of obesity in theHFD
group. After 12 weeks of the assigned diet, rats in the HFD
group were then further divided into the following groups
(𝑛 = 6), based on supplementation or nonsupplementation
with MLE 60/Orlistat, and rats in both HFD and ND groups
were continued on their respective diets:
(i) ND: normal diet only.
(ii) HFD: high fat diet only.
(iii) HFD + 250: high fat diet + 250mg/kg body weight
MLE 60.
(iv) HFD + 500: high fat diet + 500mg/kg body weight
MLE 60.
(v) HFD + OR: high fat diet + 30mg/kg body weight
Orlistat.
Orlistat, the currently available pancreatic lipase inhibitor,
was used as positive control. An overview of the experiment
is given in Figure 1.
2.3. Administration of MLE 60. Animals were allowed their
respective diets ad libitum and required dosage of MLE 60
was given through gastric intubation. Volume of extracts
given per day did not exceed 3mL. Control groups (ND
and HFD) received the vehicle (0.03% CMC) through gastric
intubation. Body weight and food intake of each rat were
recorded weekly.
2.4. Urine, Serum, and Feces Collection. Animals were placed
in individual metabolic cages at the initial, middle, and final
stages of the experiment. Urine was collected over 24 hours
in tubes containing 1% sodium azide, transferred to urine
specimen bottles, and stored at −80∘C until being analysed.
Blood samples were collected by cardiac puncture and serum
and plasma samples were separated at 1500×g for 15 minutes
and stored at −80∘C for further analysis. Feces were collected
and stored in airtight containers at−80∘C for further analysis.
2.5. Sacrifice of Animals. After 12 weeks of obesity induc-
tion and 9 weeks of treatment, animals were weighed and
sacrificed by cardiac puncture under an anaesthetic effect
(xylazine + ketamine). Rats were deprived of food for
12 h prior to sacrifice. Serum and plasma samples were
separated at 1500×g for 15 minutes and stored at −80∘C
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Figure 1: Schematic diagram of the experimental design to assess the antiobesity effect of MLE 60 in HFD induced obese male Sprague-
Dawley rats.
for further analysis. All animals were handled according
to the international principles of the Use and Handling of
Experimental Animals (United States National Institute of
Health, 1985) and all the protocols were approved by the
AnimalHouse andUseCommittee of the Faculty ofMedicine
and Health Sciences, Universiti Putra Malaysia (Approval
number UPM/FPSK/PADS/BR.UUH/00462).
2.6. Clinical Chemistry Measurements. Various biochemi-
cal parameters were measured, including blood glucose
(One Touch Basic glucose monitor, LifeScan), lipids profiles
(Roche Diagnostics GmbH, Sandhofer Strasse, Mannheim),
total cholesterol (TC), total triglycerides (TG), low den-
sity lipoprotein (LDL), high density lipoprotein (HDL),
kidney function tests (creatinine and urea), liver function
tests 𝛾-glutamyltransferase (GGT), alanine aminotransferase
(ALT), aspartate aminotransferase (AST), alkaline phos-
phatase (ALP), leptin (RayBio Rat Leptin ELISA kit, Cat#
ELR-Leptin-001, Norcross, GA, USA), insulin (Mercodia Rat
Insulin ELISA, Uppsala, Sweden), adiponectin (Assay-Max
Rat Adiponectin ELISA kit, Cat# ERA2500-1), and ghrelin
(RayBio Rat Ghrelin ELISA kit, Cat# EIA-GHR-1, Norcross,
GS,USA). All procedureswere carried out in accordancewith
the manufacturers’ instruction.
2.7. Determination of Fecal Fat Content. Fecal lipid content
was determined according to a modified method of Tsujita
et al. [23]. Feces were collected at the initial and final stages
of the experiment and stored at −80∘C until further analysis.
Feces (0.5 g) were soaked in 2mL of deionized water for
24 hours at 4∘C, followed by homogenisation by vortexing
at high speed for 60 seconds. Lipids were extracted with
7.5mL of methanol : chloroform (2 : 1, v : v) and shaken for
30 minutes, followed by addition of 2.5mL of deionized
water and 2.5mL of chloroform and further shaking for 30
minutes. Mixture was then centrifuged at 2000 g for 15min
and the lipophilic layer from the extraction was collected and
dried under vacuum. Total fat content was weighed using a
laboratory balance.
2.8. 1H NMR Analysis of Urine and Serum. 1HNMR analysis
of urine and serum was carried out following the method
of Beckonert et al. [12]. Urine samples were thawed and
centrifuged at 12 000×g for 10 minutes. 400𝜇L of the
supernatantwasmixedwith 200𝜇Lphosphate buffer solution
consisting of 0.1% of 3-trimethylsilyl propionic-2,2,3,3-d4
acid sodium salt (TSP) as internal standard (adjusted to pH
7.4 using NaOD) and transferred into 5mm NMR tubes.
Spectra were acquired at 27∘C on a Varian Unity INOVA
500MHz spectrometer (Varian Inc., CA), with a frequency of
499.887MHz. Standard one-dimensional (1D)NOESY-presat
pulse sequence was used for suppression of the water peak.
For each sample, 64 scans were recorded with an acquisition
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time of 1.36 s, pulse width of 3.75 𝜇s, and relaxation delay of
1.0 s.
For serum, thawed samples were centrifuged at 12 000×g
for 10 minutes and 200𝜇L of the supernatant was mixed
with 400𝜇L of phosphate buffer containing 0.2% TSP and
transferred into 5mm NMR tubes. In addition to the
NOESY-presat experiments, water suppressed Carr-Purcell-
Meiboom-Gill (CPMG) spin-echo pulse was performed to
suppress broad signals from macromolecules. The CPMG
spectra were acquired with 128 transients, with an acquisition
time of 1.36 s, relaxation delay of 2.0 s, and number of loops
of 𝑛 = 80.
Additional two-dimensional 1H-1H J resolved and 1H-
13C HMBC analysis was performed to confirm the identity
of certain metabolites.
2.9. NMR Spectral Data Reduction and Multivariate Data
Analysis. Chenomx NMR Suite (Chenomx, Calgary,
Canada) was used for metabolite identification and
quantification. Nonzero filled spectra were manually phased
and baseline corrected, calibrated to TSP at 0.00 ppm.
Processed spectra (𝛿 0−10 ppm) were segmented (0.04 ppm)
using the profiler module. Residual signals of water (𝛿
4.75–𝛿 4.85) and urea (𝛿 5.50–𝛿 6.00 ppm) were excluded
from analysis. Remaining bins were normalized to the sum
of spectral integrals, extracted with Microsoft Excel, and
imported into Simca-P software (Umetrics, Umea˚, Sweden)
for multivariate data analysis.
Multivariate data analysis was performed using the mean
centering with Pareto scaling. Principal component anal-
ysis (PCA) was selected as the initial clustering method.
Partial Least Squares Discriminant Analysis (PLS-DA) was
further performed as a supervised pattern recognition anal-
ysis, which maximizes the variation between the different
groups and identifies variables responsible for the separation.
Orthogonal projections to latent structures-discriminant
analysis (OPLS-DA) were also performed for biomarkers
analysis between the obese and lean groups and any metabo-
lite changes associated with MLE 60 treatment [24].
2.10. Statistical Analysis. Data are expressed as mean ± stan-
dard deviation (SD). Difference between groups was deter-
mined by one-way analysis of variance (ANOVA, Minitab
Version 14.0). Values were considered to be significantly
different at the level of 𝑝 < 0.05. For analysis of fecal
fat content (week 6 and week 12) and body weight (before
and after treatment), significance was further confirmed with
one-sample 𝑡-test.
3. Results and Discussion
3.1. Induction of Obesity in Sprague-Dawley Rats Using a High
Saturated Fat Diet. After 12 weeks of either the HFD or the
ND, rats on the HFD had significantly higher weight gain
as compared to rats on the ND. Sprague-Dawley rats on
the HFD put on 157.54 ± 39.54% of their original weight
whereas rats on the ND gained 93.34±13.82%. Other obesity
related biomarkers such as total triglycerides (TG), total
Table 1: The plasma biochemistry of rats fed a normal diet (ND) or
a high fat diet (HFD) for 12 weeks to induce obesity.
ND HFD
Total cholesterol (mmol/L) 1.28 ± 0.15a 1.16 ± 0.09a
HDL (mmol/L) 0.99 ± 0.16a 0.66 ± 0.08b
LDL (mmol/L) 0.28 ± 0.02a 0.23 ± 0.03a
Triglycerides (mmol/L) 0.43 ± 0.07a 0.91 ± 0.15b
Leptin (pg/mL) 719.30 ± 150.1a 1819.50 ± 150.1b
Insulin (𝜇g/L) 0.20 ± 0.02a 1.30 ± 0.09b
Adiponectin (ng/mL) 7.40 ± 0.50a 6.11 ± 0.07b
Glucose (mmol/L) 5.68 ± 0.33a 6.26 ± 0.13b
Urea (𝜇mol/L) 6.26 ± 0.81a 5.14 ± 0.80a
Creatinine (mmol/L) 55.20 ± 2.17a 51.60 ± 2.41a
GGT (U/L) 1.00 ± 0.00a 6.00 ± 0.84b
AST (U/L) 76.36 ± 3.16a 75.40 ± 1.29a
ALT (U/L) 37.64 ± 5.26a 30.82 ± 1.48b
ALP (U/L) 69.14 ± 9.98a 127.20 ± 5.07b
Different small letters indicate significant difference (𝑝 < 0.05) between ND
and HFD groups as shown by analysis of variance (ANOVA) using Minitab
Version 14.
cholesterol (TC), low density lipoprotein (LDL), and high
density lipoprotein (HDL) levels in the plasma were also
affected by the diet intervention (Table 1). Obese rats had
lower HDL level (0.65 ± 0.08mmol/L) as compared to lean
rats (0.986 ± 0.16). There was no significant difference in the
plasma TC and LDL content in both groups.TheTG level was
significantly (𝑝 < 0.05) elevated in the group fed the HFD
(0.908±0.15mmol/L) as compared to rats fed theND (0.432±
0.07). Obese rats had higher fasting glucose levels than lean
rats, though still in the normal range. Other obesity related
adipocytic factors such as leptin and insulin were elevated
in the obese models. Kidney function tests as measured by
plasma urea and creatinine levels appeared normal, with
no significant difference between the groups. In terms of
liver function, GGT, ALT, and ALP levels were increased
in obese rats fed the HFD. Hypercaloric diets ranging from
3.7 to 5.5 kcal/g result in models of obesity, which represent
the aetiology of obesity at its best and reproduce its patho-
physiological characteristics [25]. The increase in weight
gain is gradual as the intervention progresses. Based on the
changes in lipid profiles and other plasma biochemistries,
our study, which uses HFD containing 36% of total calories
from coconut oil, supports the theory that coconut/lard based
high fat diets do model the metabolic disorders of human
obesity in rodents [26, 27]. More specifically, a hydrogenated
coconut oil (HCO) based HFD has previously caused weight
gain, increased liver weight, and hyperlipidaemia in rats [28].
Based on the significant increase in body weight and other
biochemical parametersmeasured, we can conclude that high
fat diet induced obesity was successfully achieved in male
Sprague-Dawley rats after a feeding period of 12 weeks.
3.2. 1H NMR Spectra of Urine and Serum Metabolites of
Sprague-Dawley Rats FedHFDorND for 12Weeks. Represen-
tatives of 1H NMR spectra for the serum and urine samples
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Figure 2: Typical 500MHz 1H NMR spectra of serum collected
from a Sprague-Dawley rat fed a normal diet (lean) and a Sprague-
Dawley rat fed a high fat diet (obese).
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Obese 
Lean 
5.0 0.010.0
5.0 0.010.0
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Figure 3: Typical 500MHz 1HNMR spectra of urine collected from
a Sprague-Dawley rat fed a high fat diet (obese) and a Sprague-
Dawley rat fed a normal diet (lean).
from an obese rat fed HFD and a lean rat fed ND for 12
weeks are shown in Figures 2 and 3, respectively. Expanded
regions for better comparison are available in Supplementary
Data sections in Supplementary Material available online
at http://dx.doi.org/10.1155/2016/2391592. Metabolites were
assigned based on previous studies [29, 30], the Chenomx
NMR Suite, Version 7.7 (Chenomx Inc., Edmonton, AB,
Canada), and the Human Urine and Serum Metabolome
Databases [31, 32]. Additional two-dimensional 1H-1H J
resolved and HMBC analysis was performed to aid in the
identification of certain metabolites. A list of the identified
metabolites, including their chemical shifts, is represented in
Table 2.
CV ANOVA was used to test the significance of the
models, whereby significance is achieved with a 𝑝 value less
than 0.05. Both PLS-DA and OPLS-DAmodels for urine and
serum were validated accordingly (Table 3).
Table 2: 1H NMR assignments of metabolites in rat’s serum and
urine.
Metabolites Assignments Chemical shifts Samples
Urea NH
2
5.78 (s) U
Phenylacetylglycine
2,6-CH 7.42 (m)
U3,5-CH, 7.57 (m)
7-CH 7.65 (m)
10-CH 7.84 (m)
Trigonelline
𝛾CH
3
4.43 (s)
UC2H 8.1 (m)
C
4
H 8.8 (m)
C
5
H, 9.1 (s)
Hippurate
CH
2
, 3.98 (d)
UCH 7.54 (d)
CH 7.65 (t)
Acetate CH
3
1.93 (s) U, S
Dimethylamine CH
3
2.71 (s) U
Citrate 1/2CH2 2.54 (d) U
1/2CH
2
2.66 (d)
2-Oxoglutarate CH2 2.45 (t) U
CH
3
3.02 (t)
Creatinine CH3, 3.06 (s) U
CH
2
4.06 (s)
Lactate CH3, 1.34 (d) U, S
CH 4.11 (dd)
Β-Glucose 1-CH 4.66 (d) U, S
𝛼-Glucose 1-CH 5.22 (d) U, S
Allantoin CH 5.38 (s) U
Glycine CH
2
3.57 (s) U
Taurine CH2S, 3.26 (t) U, S
CH
2
-N 3.40 (t)
TMAO N (CH3)3 3.26 (s) U
Alanine 𝛽CH3, 3.78 (dd) S
𝛼CH 1.48 (d)
Pyruvate 𝛽CH
3
2.38 (s) S
Succinate CH 2.41 (s) S
Acetoacetate CH
3
2.27 (s) S
3-Hydroxybutyrate
𝛾CH
3
1.18 (d)
S𝛽CH 4.23 (m)
𝛼CH
2
2.31 (d)
𝛼CH
2
2.38 (dd)
2-Hydroxyisobutyrate CH
3
1.34 (s) S
Lipoprotein CH3 (CH2)𝑛 0.89 (m) S
LDL/VLDL CH
3
CH
2
CH
2
C= 1.2–1.30 (m) S
s: singlet; d: doublet; t: triplet; dd: doublet of doublets; m: multiplet.
S: serum; U: urine.
The variable importance in project (VIP) plots were
generated to identify metabolites contributing significantly
to the separation of the obese and the lean groups. A cut-
off value of 0.7-0.8 for the VIP is generally acceptable. In this
study, the cut-off value was set at 1.0 [24].
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Figure 4: OPLS-DA derived score plot (a), loading plot (b), and 𝑆 plot (c) obtained using 1H NMR data for serum samples from Sprague-
Dawley rats fed a high fat diet (HFD) or a normal diet (ND) for 12 weeks.
Table 3: PLSDA and OPLS-DA models validation for serum and
urine of Sprague-Dawley rats fed a high fat diet (HFD) or a normal
diet (ND) for 12 weeks.
Samples/models 𝑅2𝑌 𝑄2𝑌 p CVANOVA
Number of
components
Serum
PLS-DA 0.830 0.752 3.32 × 10−6 2
OPLS-DA 0.987 0.936 4.26 × 10−7 2
Urine
PLS-DA 0.917 0.874 3.18 × 10−12 3
OPLS-DA 0.959 0.923 1.89 × 10−12 3
An OPLS-DA model was used to identify discriminating
metabolites between the 2 groups fed the different diets. The
OPLS-DA method is useful for biomarkers identification.
The 𝑆 plot was further used to visualise the influence of the
variables in the model by considering both covariance 𝑝(1)
and correlation 𝑝(corr) loadings profiles from the OPLS-
DA model. This enables filtering interesting metabolites in
the projection. Ideal biomarkers have high magnitude and
reliability values (Figures 4 and 5).
Induction of obesity was associated with increased
serum levels of acetate, succinate, pyruvate, VLDL/LDL, and
acetoacetate and decreased levels of lactate, 2-hydroxyis-
obutyrate, and betaine, among others (Figure 4). The same
principle was applied to the analysis of urine and clear
separation was obvious in the 1H NMR profiles (Figure 5).
Among the increased metabolites in the HFD group were
the levels of creatinine, allantoin, taurine, and phenylacetyl-
glycine, while the levels of 2-oxoglutarate, dimethylamine,
citrate, and hippurate were decreased.
After 12 weeks of feeding on the HFD, male Sprague-
Dawley rats had a significantly (𝑝 < 0.05) higher increase
in body weight as compared to rats fed ND. Obese rats
had higher plasma level of TG and lower level of HDL as
compared to their lean counterparts. TC and LDL levels
were not significantly changed in the 2 groups fed ND
and HFD. 1H NMR analysis of urine and serum revealed
additional metabolic changes, beyond the measured small
set of parameters. OPLS-DA analysis of serum 1H NMR
spectra revealed increased succinate, pyruvate, VLDL/LDL,
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Figure 5: OPLS-DA derived score plot (a), loading plot (b), and 𝑆 plot (c) obtained using 1H NMR data for urine samples from Sprague-
Dawley rats fed a high fat diet (HFD) or a normal diet (ND) for 12 weeks.
and acetoacetate and decreased lactate, betaine, and taurine
levels in the HFD group. OPLS-DA analysis of urine samples
showed that rats fed HFD had higher urinary content of
creatinine, allantoin, taurine, and phenylacetylglycine and
decreased levels of 2-oxoglutarate, dimethylamine, citrate,
and hippurate.
All of these identified metabolites are related to vari-
ous metabolic pathways, namely, the glucose metabolism
and tricarboxylic acid (TCA) cycle, lipid metabolism,
choline metabolism, amino acids metabolism, and creatinine
metabolism.
Glucose Metabolism and TCA Cycle. Obese rats had higher
succinate, pyruvate, acetoacetate, and acetate levels and
decreased levels of lactate, 2-oxoglutarate, and citrate, all
metabolites related to the glucose metabolism and the TCA
cycle. These findings are consistent with other reports on
the metabolomics studies of obesity [14, 33, 34]. This current
study showed decreased serum lactate in obese rats fed HFD
for 12 weeks, which is similar to the study of Song et al. [16]
where hyperlipidemic mice fed HFD had decreased level of
lactate. The urine of Zucker rats and the serum of HFD mice
also had lower lactate content than the normalweight rats and
the serum [14, 35].The reduced lactate levels can be explained
by factors other than HFD induced obesity, including young
age and activity [36].
HFD induced obese rats had lower urinary content of
2-oxoglutarate and citrate as compared to the lean rats.
Previously, Schirra et al. [37] reported a decreased level of
2-oxoglutarate in 2 mutants groups studied for altered liver
metabolism. The level of citrate in the plasma is regulated by
insulin, glucose levels, fatty acid utilization, and cholesterol
synthesis [38] and is usually increased in HFD obese models
[39] and diabetic models [40]. However, consistent with
our findings, HFD induced rodents have decreased urinary
citrate levels [37] which is associated with insulin resistance
in humans [41]. Independent measurement of plasma insulin
in this study showed a 6-fold increase in the insulin level
of HFD fed obese rats (1.29 𝜇g/L) as opposed to the ND fed
lean rats (0.21 𝜇g/L), which indicates that the HFD not only
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induced obesity in the rodents, but also caused the model to
be insulin resistant, most likely caused by decreased urinary
citrate excretion due to an increase inmetabolic acidosis [42].
With lactate being the precursor for gluconeogenesis,
any fluctuation in lactate levels indicates perturbations in
glucose production and lipid synthesis in the liver [43].
The downregulation of pyruvate dehydrogenase phosphatase
in obese subjects has been reported to be a defect, which
signals insulin resistance [44]. Elevated concentrations of
pyruvate suggest increased glycogenolysis and glycolysis to
meet exceeding energy demands, similarly to the observation
of serum profile of obese growing pigs [45].
Lipid Metabolism. The levels of betaine and taurine were
changed as a result of the HFD, revealing changes in lipid
metabolic pathways. Serum profiles showed lower levels of
taurine, while there was an increased level of urinary taurine
content. Previous studies have reported reduced taurine
content in the serum, urine, and liver of various rodent
models [14]. However, also in accordance with our findings,
Kim et al. [13] reported increased levels of taurine in the
urine of HFD fed rats. Taurine plays various biological roles
in the conjugation of cholesterol, antioxidation of bile acids,
osmoregulation, and calcium signalling pathways [46, 47].
The supplementation of taurine showed amelioration in obe-
sity most likely mediated by the ability of taurine to increase
fatty acid oxidation [48]. This study shows decreased taurine
in the obese group, suggesting decreased fatty acids oxidation
and inhibition of taurine biosynthetic enzymes related to
obesity, as observed by increased levels of LDL/VLDL shown
in both serum spectra and actual measured values.
Choline Metabolism. Pertaining to choline metabolism, the
level of betaine was decreased in the HFD group, simi-
larly to most metabolomics based obesity studies reporting
decreased hepatic and urinary betaine content in HFD fed
rodents [33, 34] and decreased hippurate in the serumofHFD
mice [38]. In humans, lowered betaine levels are associated
with obesity related disorders such as metabolic disorders,
lipid disorders, and type 2 diabetes [49]. Supplementation
of betaine causes increase in metabolites in the carnitine
biosynthesis pathway, reduced accumulation of triglycerides
in the liver, with no effect on body weight gain and increase
in adipose tissue mass [50].
Creatinine Metabolism. Feeding of HFD diet for 12 weeks
resulted in increased creatinine levels in the urine samples,
in line with other reports [37, 51, 52].
Amino Acids Metabolism. High level of serum acetoacetate
might be the indication of depletion in leucine level, an
amino acid involved in insulin signalling, protein synthesis of
muscle mass, and production of alanine and glutamine [53].
Alanine peaks were more prominent in the serum spectra of
the lean rats as compared to obese subjects.
Gut Microbiome Metabolism. Changes in specific metabolites
support the idea that there is a link between obesity and
the gut microbiome. HFD induced obese rats showed high
urinary content of phenylacetylglycine and decreased levels
of hippurate and dimethylamines, metabolites involved in
the gut microbiome metabolism. Hippurate is produced in
the gut by microorganisms using glycine and benzoic acid as
building blocks [54]. Increased hippurate level in the urine
has been associated with leanness [34] and this study con-
firms the findings from other studies [38] that HFD induced
obesity is associatedwith decreased urinary level of hippurate
in rodent models of obesity. Increased levels of phenylacetyl-
glycine in Sprague-Dawley rats fedHFDhave been previously
reported [13]. High gainers fed HFD were associated with
increased levels of phenylacetylglycine as compared to low
gainers on ND, which indicates an increase in the precursors
produced by gut microorganisms [55]. Moreover, reduced
dimethylamine levels in the obese group reflect changes in
the gut microbiome derived metabolism, similarly to what
is observed in leptin-deficient ob/ob mice [56]. Trigonelline
was also identified in the urine samples of lean rats. It
is an indicator of niacin metabolism, an essential vitamin
needed as coenzyme in carbohydrate and lipid metabolism.
The body’s requirements for niacin can be met by dietary
intake or endogenous biosynthesis through tryptophan-
mediated metabolism carried out by the liver and the gut
microorganisms [57]. Obesity related stress causes depletion
in the glutathione stores and the decrease of trigonelline is
related to depletion of 𝑆-adenosylmethionine, used to make
up the energy stores [58]. A strong link between human
gut microbiome and obesity was established with decreased
urinary excretion of hippurate, trigonelline, and xanthine
and increased urinary excretion of 2-hydroxybutyrate and
bariatric surgery induced weight loss resulted in the loss of
typical obese metabotype [59].
3.3. Effect of 9-Week Treatment with 250/500mg/kg of MLE
in the Obese Rats Models. After 12 weeks of inducing obesity,
rats on the HFD were further divided and received either
MLE 60 (250 and 500mg/kg), Orlistat (30mg/kg), or the
carrier vehicle (CMC). Obese rats were kept on the HFD
while lean rats were continued on the ND. Body weight
and food intake were recorded weekly and the plasma
biochemistry was analysed at the end of the experiment
(Table 4).
Although there was no significant weight loss in the obese
group, receiving MLE 60 or Orlistat, further weight gain was
prevented in theHFD+ 500 andHFD+ORgroup. Treatment
resulted in reduced visceral fat, with the HFD group having
the highest amount (6.62 ± 1.54%). The treated groups had
a reduced % of visceral fat ranging from 3.34 ± 0.99 for
the HFD + OR group to 4.87 ± 0.96% for the HFD + 500
group. There was no significant difference in decrease of
visceral fat between the obese rats receiving 500mg/kg MLE
60 and rats receiving standard antiobesity drug, Orlistat. No
significant difference was recorded in the daily food intake
among all groups. At baseline (before treatment), there was
no significant difference in the fecal fat excretion in the lean
and obese rats. Treatment with 500mg/kgMLE increased the
fecal fat excretion (12.64±1.73%), with a comparable effect to
treatment with Orlistat (15.89 ± 1.62%). The fecal fat content
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Table 4:The body weight, % visceral fat, food intake, % fecal fat excretion, and plasma biochemistry of HFD induced obese rats after 9 weeks
of treatment with MLE 60 at 250mg/kg and 500mg/kg body and 30mg Orlistat/kg body weight.
HFD HFD + 250 HFD + 500 HFD + OR ND
Body weight (g)
Initial (week 12) 559.20 ± 25.89Bb 546.85 ± 83.20Bb 544.29 ± 78.74Bb 537.25 ± 93.83Bb 379.33 ± 34.82Aa
Final (week 21) 614.20 ± 131.58Bb 605.57 ± 101.50Bb 565.85 ± 87.47Bb 553.13 ± 98.93Bb 417.16 ± 32.99Aa
Visceral fat (%) 6.62 ± 1.54c 5.18 ± 0.40bc 4.87 ± 0.963b 3.34 ± 0.99b 1.70 ± 0.28a
Food intake (g/rat/day) 20.00 ± 3.09a 19.08 ± 2.29a 19.38 ± 2.01a 19.08 ± 0.86a 20.17 ± 1.35a
Fecal fat content (%)
Initial 6.18 ± 1.19aA 7.35 ± 1.14aA 6.31 ± 1.40aA 6.12 ± 1.52aA 7.64 ± 0.70aA
Final 7.23 ± 1.01aC 9.44 ± 1.07aC 12.64 ± 1.73bB 15.89 ± 1.62bA 8.99 ± 0.61aC
Total cholesterol (mmol/L) 1.43 ± 0.08b 1.04 ± 0.01a 0.94 ± 0.02a 0.92 ± 0.07a 1.29 ± 0.13b
HDL (mmol/L) 0.82 ± 0.06b 0.57 ± 0.12bc 0.69 ± 0.07b 0.56 ± 0.01c 1.02 ± 0.09a
LDL (mmol/L) 0.33 ± 0.07b 0.22 ± 0.03ab 0.17 ± 0.03a 0.20 ± 0.04a 0.21 ± 0.05a
Triglycerides (mmol/L) 0.93 ± 0.16c 0.72 ± 0.12bc 0.50 ± 0.11ab 0.58 ± 0.01ab 0.42 ± 0.09a
Leptin (pg/mL) 2119.50 ± 176.3b 1563.30 ± 556.9ab 1050.00 ± 229.3a 1263.30 ± 30.10a 1125.00 ± 117.60a
Insulin (𝜇g/L) 1.83 ± 0.10c 0.71 ± 0.01b 0.37 ± 0.13a 0.47 ± 0.22ab 0.31 ± 0.01a
Ghrelin (ng/mL) 25.7 ± 3.71c 54.57 ± 4.19a 35.74 ± 1.68b 37.63 ± 0.98b 53.01 ± 1.95a
Adiponectin (ng/mL) 8.61 ± 0.77b 9.50 ± 0.23ab 9.25 ± 0.50ab 8.25 ± 0.44b 9.87 ± 0.20a
Glucose (mmol/L) 7.70 ± 0.78c 6.85 ± 0.71bc 5.83 ± 0.53ab 4.98 ± 0.17a 6.03 ± 0.17b
Different small letters indicate significant difference (𝑝 < 0.05) between different groups and different capital letters indicate significant difference among the
same group at different time points, as shown by analysis of variance (ANOVA) using Minitab Version 14.
in the control group (HFD only) remained unchanged after 9
weeks (7.23 ± 1.01%).
Few plasma parameters were measured after 9 weeks of
treatment (Table 4). With regard to lipid profiles, treatment
with both 500mg MLE 60/kg and Orlistat improved the
plasma LDL level, reducing its levels to the LDL profile of lean
rats. The treatment, however, failed to improve HDL levels,
with the HFD + OR group having the lowest plasma HDL
content of 0.56 ± 0.01mmol/L. Lean rats on the ND have the
highest level of HDL, 1.02 ± 0.09mmol/L. The most marked
effect was in the TG content, wherebyHFD+ 500 (0.50±0.11)
significantly improved the plasma TG level as compared to
rats receiving the HFD only (0.93 ± 0.12).
The plasma insulin level was significantly improved in
the HFD + 500 group (0.37 ± 0.13), which was similar
to the ND group (0.31 ± 0.02). Similarly, plasma leptin
levels were significantly improved in both HFD + 500
group (1050 ± 229 pg/mL) and HFD + OR group (1263 ±
30.10 pg/mL) as compared with the HFD group (2119 ±
176 pg/mL). Ghrelin levels were improved in all treated
groups, with 250mg/kg dosage being more potent, restoring
the ghrelin levels to 54.57 ng/mL, not significantly different
from the lean group (53.01 ng/mL). Adiponectin levels were
not significantly different in the lean groups and the treated
groups (9.25–9.87 ng/mL), except in the group treated with
Orlistat (8.25 ng/mL), where the adiponectin level was not
significantly different from the obese group (8.61 ng/mL).
Treatmentwith 30mg/kgOrlistat and 500mg/kgMLE60 had
the most significant improvement.
In the previous section, rats fedHFDwere associatedwith
higher acetate and pyruvate and surprisingly lower lactate
levels as opposed to lean rats fed ND. After an additional
9 weeks, rats fed HFD were still associated with higher
acetate and pyruvate and also higher lactate level. Lactate
is one of the key metabolites related to glucose metabolism
and the TCA cycle, which has been reported to be higher
in obese humans [60]. Increased lactate concentration has
been attributed to the upregulation in anaerobic glycolysis
in obese subjects and the balance between lactate production
and lactate removal [14, 61]. The adipose tissue is one of the
sites of lactate production, together with the skeletal muscles,
erythrocytes, and brain [61, 62]. Increased lactate production
can also reflect perturbations in glucose and lipid production
in the liver due to the involvement of lactate as a precursor
in gluconeogenesis [43] with increased serum lactate being
associated with increased risk of mortality [63]. In this study,
increased serum lactate in the HFD group can be attributed
to the higher percentage of body fat as compared to the
lean rats. Lactate levels in obese subjects are also highly
dependent on insulin resistance [64]. In a study by Chen et
al., normal weight subjects with normal blood glucose had
the lowest plasma lactate levels, obese subjects with normal
blood glucose had intermediate plasma lactate levels, and
obese subjects with impaired blood glucose had the highest
lactate levels. Consistent with these reports, this study shows
that, after 21 weeks of feeding HFD, rats had higher insulin
levels (1.83 𝜇g/L) as compared to after 12 weeks of feeding
(1.30 𝜇g/L), which explains the elevated lactate levels in the
obese groups. Treated groups had significant decrease in % of
body fat and plasma insulin levels, which contributes to the
decreased lactate plasma content [65].
Another metabolite, which was found to be strongly
associatedwith obesity, is 2-hydroxyisobutyrate. It is involved
in the gut microbiome metabolism and has been reported to
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Table 5: Relative quantification of significant discriminating metabolites based on the concentration of 0.1% of 3-trimethylsilyl propionic-
2,2,3,3-d4 acid sodium salt (TSP) as internal standard and quantified using Chenomx NMR Suite.
Metabolites Chemical shifts VIP value HFD ND HFD + 250 HFD + OR p value
Lactate 1.34 (d) 2.46 1662.9 ± 51.9c 493.4 ± 73.1a 482.1 ± 55.9a 761.0 ± 33.6b 0.000
4.11 (dd)
Alanine 3.78 (dd) 1.63 94.0 ± 3.03b 53.3 ± 13.48a 55.6 ± 3.52a 47.0 ± 2.50a 0.002
1.48 (d)
3-Hydroxybutyrate
1.18 (d)
3.48 316.8 ± 23.17b 513.8 ± 74.20a 368.7 ± 24.00ab 396.9 ± 73.54ab 0.0234.23 (m)
2.31 (d)
2.38 (dd)
2-Hydroxyisobutyrate 1.34 (s) 5.60 232.5 ± 25.36b 153.8 ± 15.12a 143.9 ± 21.54a 182.1 ± 49.43ab 0.036
Pyruvate 2.38 (s) 2.19 55.6 ± 3.62c 18.7 ± 2.16a 31.1 ± 1.03b 28.3 ± 7.21b 0.000
Creatinine/creatine 3.06 (s) 1.28 45.1 ± 2.43b 25.6 ± 3.64a 23.3 ± 0.60a 39.5 ± 0.04b 0.000
4.06 (s)
𝛼-Glucose 5.22 (d) 1.09 1116.4 ± 27.4c 458.1 ± 27.6b 511.7 ± 20.6b 206.4 ± 44.3a 0.000
Acetate 1.93 (s) 1.28 38.9 ± 2.80b 26.8 ± 4.42a 35.4 ± 1.50b 38.9 ± 2.61b 0.013
Different small letters indicate significant difference (𝑝 < 0.05) between different groups as shown by the analysis of variance (ANOVA) usingMinitab Version
14.
be altered in leptin-deficient ob/ob mice [56] and increased
in obese patients [66].
Regarding amino acid metabolism, serum alanine was
increased in HFD group as compared to the lean group, in
line with previous studies reporting increased alanine in the
serum and liver of HFD induced mice and rats [39].
Obesity was characterised by decreased levels of 3-
hydroxybutyrate, a metabolite of amino acid metabolism,
which is associated with leanness and weight loss, where
obese patients expressed the highest 3-hydroxybutyrate levels
following bariatric surgery [66]. Early studies have also
reported on the link between obesity and 3-hydroxybutyrate.
Administration of the compound in obese subjects on
low energy diets resulted in improved fat : lean ratio while
not affecting weight loss [67]. The roles of acetoacetate
and 3-hydroxybutyrate were further studied in obese and
insulin dependent diabetic humans using a kinetic approach,
to investigate ketone body metabolism. Obese subjects
had lower ketone body de novo synthesis, with no sig-
nificant clearance of 3-hydroxybutyrate from the normal
healthy subjects, with 3-hydroxybutyrate being an impor-
tant determinant in diabetic ketoacidosis [68]. Moreover, 3-
hydroxybutyrate has also been associated with reduced food
intake in obese subjects [69] and involved in the short-term
and long-term effects of high fat diet in mice [14]. Won et
al. also reported the downregulation of 2-hydroxybutyrate in
both male and female leptin-deficient ob/ob mice [56].
In the metabolites identification, OPLS-DA model con-
sisting of 2 groups at a time was employed, followed by
the Shared and Unique Structure (SUS) plots, to compare
biomarkers from 2 models.
Key discriminating metabolites as potential biomarkers
in rat serum based on 1H NMR loading plots in the HFD,
HFD + 500, and ND groups were quantified, relative to
the TSP in the serum samples. Statistical analysis (Minitab
Version 14) was further employed to detect significance.
Focus was placed on metabolites with a VIP value of >1,
as metabolites contributing more to the clustering of the
different groups (Table 5).
There are limited studies, which have used a metabo-
lomics approach to identify metabolic changes following
intervention with drugs and therapeutics, including the phy-
tochemical strategies for obesity, though the potential is vast
[70]. However, there are few metabolomics based reports on
weight loss as a result of weight loss intervention, including
exercise and surgery. An energy-restricted diet for 8 weeks
resulted in an improvement in glucose and lipid metabolism
in overweight obese adults. Saturated fatty acids such as
palmitic acid and stearic acid were significantly decreased as
well as branched amino acid, isoleucine [71]. A lifestyle inter-
vention in obese children, “Obeldicks,” resulted in significant
weight loss and abdominal obesity, modulated by the role
of phosphatidylcholine metabolism. This particular study
also highlights the large interindividual variation to lifestyle
intervention and the possible need of a more individualised
approach to lifestyle interventions [72]. 1H NMR analysis
also showed that while exercise can improve the metabolic
disruptions associated with diet induced obesity, the effect
cannot be cancelled out and diet predicts obesity better with a
stronger influence onmetabolites’ profiles than exercise alone
[14].
One of the few studies reporting the response of natu-
ral therapeutic agents in obese subjects assessed the effect
of sea buckhorn and bilberry on serum metabolites in
overweight women. No significant changes were observed
in individual metabolites, though improvements in serum
lipids and lipoproteins were observed [73]. The treatment
of high fat diet induced hyperlipidemia with Xue-Fu-Zhu-
Yu decoction was studied using a NMR based metabolomics
approach. OPLS-DA analysis revealed the beneficial effects
of the decoction, mainly through decrease in ketone bodies
production, enhancement of biosynthesis, andmodulation of
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lipid metabolism [16]. Dietary intervention of black soybean
peptides in overweight human showed an increase in betaine,
benzoic acid, pyroglutamic acid, and pipecolic acid, among
others. VIP analysis showed L-proline, betaine, and lyso-PCs
to be more correlated to the discrimination before and after
treatment [74].
Treatment with MLE 60 at 250mg/kg body weight
improved serum levels of lactate, alanine, pyruvate, crea-
tinine, and 𝛼-glucose, bringing their levels closer to the
normal control whereas the level of 3-hydroxyisobutyrate,
3-hydroxybutyrate, and acetate remained unchanged. Sim-
ilar improvements were achieved in the groups receiving
30mg/kg body weight of Orlistat. The relative concentration
of 𝛼-glucose was found to be most reduced, consistent
with the actual biochemical measurement done previously
where the Orlistat treated group had significantly lower
plasma glucose (4.97mmol/L) as compared to the lean group
(6.02mmol/L).This is consistent with the literature reporting
that Orlistat in a weight loss regimen can significantly
improve glucose tolerance and slows down the progression
of type 2 diabetes and impaired glucose tolerance in clinical
cases of obesity [75, 76].
Based on the relative quantification of certainmetabolites
(lactate, pyruvate, and glucose) in the treated groups, it is
apparent that treatment with MLE 60 improved perturba-
tions in various metabolic pathways, predominantly in the
glucose and TCA cycle as reflected by positive modulations
in lactate, pyruvate, and glucose levels. Disruptions in the
creatinine and amino acid metabolic pathways were also
improved as indicated by a reduction of creatinine and
alanine accumulation in the obese groups treated with MLE
60. The levels of 3-hydroxyisobutyrate, a metabolite of the
gut microbiome metabolism, were unchanged in the treated
groups, suggesting that MLE 60 did not impact on the
obesity-induced disruptions in the gut microbiome. Simi-
larly, the levels of 2-hydroxybutyrate, a metabolite of amino
acid metabolism, were also unchanged.
Obesity has been characterised by an elevated TCA
function in diet induced hepatic insulin and fatty liver as
well as decreased brain glucose metabolism, predominantly
through the TCA cycle [77, 78]. Treatment with MLE 60
improved serum creatinine profiles as shown by 1H NMR
measurement as compared to nonsignificance observedwhen
blood creatinine level was measured. Poor creatinine clear-
ance is associated with weight gain and central obesity due
to increased metabolic abnormalities as risk factors [79]. An
increase in creatine kinase and adenylate kinase 1 activity
was observed in obese subjects, attributed to a compensatory
effect of the downregulation of muscle mitochondrial func-
tion, associated with obesity [80].
Hence, antiobesity agent which can positively influence
these pathways as well as other parameters such as adipocytes
factors and weight loss shows promise for weight manage-
ment.
4. Conclusion
Based on the reported health properties of M. citrifolia,
including the antiobesity activities, the aim of this study was
to further explore the effect of a leaf extract, MLE 60, on
obesity using a 1H NMR metabolomic approach. 1H NMR
spectroscopy and multivariate data analysis revealed clear
metabolic differences in the urine and serum samples of the
HFD induced obese and lean rats. An OPLS-DAmethod was
chosen to project maximum separation between the groups
and to identify discriminating biomarkers. All multivariate
models including PLS-DA and OPLS-DA were duly vali-
dated, using permutation tests, 𝑅2𝑌,𝑄2𝑌, and 𝑝CVANOVA
values. Several metabolites were identified in both the serum
and urine samples, which were the basis of difference among
the groups. These metabolites were involved in the glucose
metabolism and TCA cycle (lactate, 2-oxoglutarate, citrate,
succinate, pyruvate, and acetate), amino acid metabolism
(alanine, 2-hydroxybutyrate), choline metabolism (betaine),
creatinine metabolism (creatinine), and gut microbiome
metabolism (hippurate, phenylacetylglycine, dimethylamine,
and trigonelline). Some key metabolites were identified and
quantified showing a statistically (𝑝 < 0.05) significant
improvement in this treated group (500mg/kg). This study,
therefore, confirms the metabolic alteration caused by HFD
induced obesity in a rat model and the improvement in cer-
tainmetabolic pathways, upon treatmentwithMLE 60. It also
provides additional information that 1HNMRmetabolomics
can be a good approach to study the development of disease
and response to treatment in obese subjects.
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